Current Treatment Options in Psychiatry

, Volume 5, Issue 1, pp 73–97 | Cite as

Treatment Implications for ADHD Youth with Mood and Anxiety Comorbidity

Child and Adolescent Psychiatry (M Brotman, Section Editor)
  • 39 Downloads
Part of the following topical collections:
  1. Topical Collection on Child and Adolescent Psychiatry

Abstract

Purpose of Review

There are multiple pharmacological and psychosocial interventions that are tolerable and efficacious for the treatment of attention deficit hyperactivity disorder (ADHD). However, many youth with ADHD have elevated levels of mood and anxiety symptoms that can complicate treatment. In this review, we summarize the relevant treatment studies on the treatment of youth with ADHD and comorbid anxiety or mood disorders.

Recent Findings

Treatment of ADHD, specifically CNS stimulants, often translates to reduced irritability in youth with ADHD, but appears to have limited impact on other mood or anxiety symptoms. The presence of ADHD does not appear to reduce the efficacy of pharmacological treatments of mood and anxiety disorders. There is less data on the impact of ADHD on psychosocial treatments for internalizing disorders.

Summary

In children with elevated levels of mood or anxiety, ADHD can be safely and effectively treated with either evidence-based pharmacological or psychosocial interventions. However, additional treatments are often needed to achieve significant improvements in other mood or anxiety symptoms.

Keywords

Attention deficit hyperactivity disorder Mood disorder Anxiety disorder Comorbidity Treatment 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. R. Baweja declares that he has no conflict of interest. Dr. Waxmonsky, in the past 3 years, received research funds from NIH and Pfizer and served as a consultant for Noven Pharmaceuticals, IronShore, Purdue Pharma, and NLS Pharma.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as follows: • Of importance

  1. 1.
    Thomas R, Sanders S, Doust J, et al. Prevalence of attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. Pediatrics. 2015;134(4):e994–1001.CrossRefGoogle Scholar
  2. 2.
    Visser SN, Bitsko RH, Danielson ML, Ghandour RM, Blumberg SJ, Schieve LA, et al. Treatment of attention deficit/hyperactivity disorder among children with special health care needs. J Pediatr. 2015;166(6):1423–30 e2.  https://doi.org/10.1016/j.jpeds.2015.02.018.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Bui AL, Dieleman JL, Hamavid H, Birger M, Chapin A, Duber HC, et al. Spending on children’s personal health care in the United States, 1996-2013. JAMA Pediatr. 2017;171(2):181–9.  https://doi.org/10.1001/jamapediatrics.2016.4086.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Steinhausen HC, Nøvik TS, Baldursson G, Curatolo P, Lorenzo MJ, Rodrigues Pereira R, et al. Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I25–9.  https://doi.org/10.1007/s00787-006-1004-y.PubMedCrossRefGoogle Scholar
  5. 5.
    Pliszka SR. Comorbidity of attention-deficit/hyperactivity disorder with psychiatric disorder: an overview. J Clin Psychiatry. 1998;59(Suppl 7):50–8.PubMedGoogle Scholar
  6. 6.
    The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56:1073–86.CrossRefGoogle Scholar
  7. 7.
    Treatment for Adolescents with Depression Study Team. The Treatment for Adolescents With Depression Study (TADS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2005;44(1):28–40.  https://doi.org/10.1097/01.chi.0000145807.09027.82.CrossRefGoogle Scholar
  8. 8.
    Meinzer MC, Pettit JW, Waxmonsky JG, Gnagy E, Molina BSG, Pelham WE. Does childhood attention-deficit/hyperactivity disorder (ADHD) predict levels of depressive symptoms during emerging adulthood? J Abnorm Child Psychol. 2016;44(4):787–97.  https://doi.org/10.1007/s10802-015-0065-0.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Chronis-Tuscano A, Molina BS, Pelham WE, et al. Very early predictors of adolescent depression and suicide attempts in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2010;67(10):1044–51.  https://doi.org/10.1001/archgenpsychiatry.2010.127.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Balazs J, Kereszteny A. Attention-deficit/hyperactivity disorder and suicide: a systematic review. World J Psychiatry. 2017;7(1):44–59.  https://doi.org/10.5498/wjp.v7.i1.44.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Kovacs M, Akiskal HS, Gatsonis C, Parrone PL. Childhood-onset dysthymic disorder. Clinical features and prospective naturalistic outcome. Arch Gen Psychiatry. 1994;51(5):365–74.  https://doi.org/10.1001/archpsyc.1994.03950050025003.PubMedCrossRefGoogle Scholar
  12. 12.
    Biederman J, Faraone S, Mick E, et al. Psychiatric comorbidity among referred juveniles with major depression: fact or artifact? J Am Acad Child Adolesc Psychiatry. 1995;34(5):579–90.  https://doi.org/10.1097/00004583-199505000-00010.PubMedCrossRefGoogle Scholar
  13. 13.
    Faraone SV, Biederman J, Mennin D, et al. Attention-deficit hyperactivity disorder with bipolar disorder: a familial subtype? J Am Acad Child Adolesc Psychiatry. 1997;36(10):1378–87.  https://doi.org/10.1097/00004583-199710000-00020.PubMedCrossRefGoogle Scholar
  14. 14.
    Findling RL, Gracious BL, McNamara NK, Youngstrom EA, Demeter CA, Branicky LA, et al. Rapid, continuous cycling and psychiatric co-morbidity in pediatric bipolar I disorder. Bipolar Disord. 2001;3(4):202–10.  https://doi.org/10.1034/j.1399-5618.2001.30405.x.PubMedCrossRefGoogle Scholar
  15. 15.
    Masi G, Perugi G, Toni C, Millepiedi S, Mucci M, Bertini N, et al. Attention-deficit hyperactivity disorder-bipolar comorbidity in children and adolescents. Bipolar Disord. 2006;8(4):373–81.  https://doi.org/10.1111/j.1399-5618.2006.00342.x.PubMedCrossRefGoogle Scholar
  16. 16.
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition ed. Washington, DC: American Psychiatric Press; 2013.  https://doi.org/10.1176/appi.books.9780890425596.CrossRefGoogle Scholar
  17. 17.
    Lochman JE, Evans SC, Burke JD, Roberts MC, Fite PJ, Reed GM, et al. An empirically based alternative to DSM-5’s disruptive mood dysregulation disorder for ICD-11. World Psychiatry. 2015;14(1):30–3.  https://doi.org/10.1002/wps.20176.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Mayes SD, Waxmonsky JD, Calhoun SL, Bixler EO. Disruptive mood dysregulation disorder symptoms and association with oppositional defiant and other disorders in a general population child sample. J Child Adolesc Psychopharmacol. 2016;26(2):101–6.  https://doi.org/10.1089/cap.2015.0074.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Copeland WE, Shanahan L, Egger H, Angold A, Costello EJ. Adult diagnostic and functional outcomes of DSM-5 disruptive mood dysregulation disorder. Am J Psychiatry. 2014;171(6):668–74.  https://doi.org/10.1176/appi.ajp.2014.13091213.PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Brotman MA, Schmajuk M, Rich BA, Dickstein DP, Guyer AE, Costello EJ, et al. Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children. Biol Psychiatry. 2006;60(9):991–7.  https://doi.org/10.1016/j.biopsych.2006.08.042.PubMedCrossRefGoogle Scholar
  21. 21.
    Stringaris A, Cohen P, Pine DS, et al. Adult outcomes of youth irritability: a 20-year prospective community-based study. Am J Psychiatry. 2009;166(9):1048–54.  https://doi.org/10.1176/appi.ajp.2009.08121849.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Baweja R, Mayes SD, Hameed U, Waxmonsky JG. Disruptive mood dysregulation disorder: current insights. Neuropsychiatr Dis Treat. 2016;12:2115–24.  https://doi.org/10.2147/NDT.S100312.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Roy AK, Lopes V, Klein RG. Disruptive mood dysregulation disorder: a new diagnostic approach to chronic irritability in youth. Am J Psychiatry. 2014;171(9):918–24.  https://doi.org/10.1176/appi.ajp.2014.13101301.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Vidal-Ribas P, Brotman MA, Valdivieso I, Leibenluft E, Stringaris A. The status of irritability in psychiatry: a conceptual and quantitative review. J Am Acad Child Adolesc Psychiatry. 2016;55(7):556–70.  https://doi.org/10.1016/j.jaac.2016.04.014.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Seymour KE, Miller L. The role of poor frustration tolerance. Curr Dev Disord Rep. 2017;4(1):14–8.  https://doi.org/10.1007/s40474-017-0105-2.CrossRefGoogle Scholar
  26. 26.
    Leibenluft E, Stoddard J. The developmental psychopathology of irritability. Dev Psychopathol. 2013;25(4pt2):1473–87.  https://doi.org/10.1017/S0954579413000722.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    March JS, Swanson JM, Arnold LE, Hoza B, Conners CK, Hinshaw SP, et al. Anxiety as a predictor and outcome variable in the multimodal treatment study of children with ADHD (MTA). J Abnorm Child Psychol. 2000;28(6):527–41.  https://doi.org/10.1023/A:1005179014321.PubMedCrossRefGoogle Scholar
  28. 28.
    Sciberras E, Lycett K, Efron D, Mensah F, Gerner B, Hiscock H. Anxiety in children with attention-deficit/hyperactivity disorder. Pediatrics. 2014;133(5):801–8.  https://doi.org/10.1542/peds.2013-3686.PubMedCrossRefGoogle Scholar
  29. 29.
    Biederman J, Faraone SV, Chen WJ. Social adjustment inventory for children and adolescents: concurrent validity in ADHD children. J Am Acad Child Adolesc Psychiatry. 1993;32(5):1059–64.  https://doi.org/10.1097/00004583-199309000-00027.PubMedCrossRefGoogle Scholar
  30. 30.
    Pliszka SR. Psychiatric comorbidities in children with attention deficit hyperactivity disorder: implications for management. Paediatr Drugs. 2003;5(11):741–50.  https://doi.org/10.2165/00148581-200305110-00003.PubMedCrossRefGoogle Scholar
  31. 31.
    Jensen PS, Shervette RE 3rd, Xenakis SN, et al. Anxiety and depressive disorders in attention deficit disorder with hyperactivity: new findings. Am J Psychiatry. 1993;150(8):1203–9.  https://doi.org/10.1176/ajp.150.8.1203.PubMedCrossRefGoogle Scholar
  32. 32.
    Spencer AE, Faraone SV, Bogucki OE, Pope AL, Uchida M, Milad MR, et al. Examining the association between posttraumatic stress disorder and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77(1):72–83.  https://doi.org/10.4088/JCP.14r09479.PubMedCrossRefGoogle Scholar
  33. 33.
    Adams Z, Adams T, Stauffacher K, Mandel H, Wang Z. The effects of inattentiveness and hyperactivity on posttraumatic stress symptoms: does a diagnosis of posttraumatic stress disorder matter? J Atten Disord. 2015:108705471558084.  https://doi.org/10.1177/1087054715580846.
  34. 34.
    Hetherington EM, Stanley-Hagan M. The adjustment of children with divorced parents: a risk and resiliency perspective. J Child Psychol Psychiatry. 1999;40(1):129–40.  https://doi.org/10.1111/1469-7610.00427.PubMedCrossRefGoogle Scholar
  35. 35.
    Biederman J, Faraone SV, Keenan K, Steingard R, Tsuang MT. Familial association between attention deficit disorder and anxiety disorders. Am J Psychiatry. 1991;148(2):251–6.  https://doi.org/10.1176/ajp.148.2.251.PubMedGoogle Scholar
  36. 36.
    Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–22.CrossRefGoogle Scholar
  37. 37.
    Patel A, Medhekar R, Ochoa-Perez M, Aparasu RR, Chan W, Sherer JT, et al. Care provision and prescribing practices of physicians treating children and adolescents with ADHD. Psychiatr Serv. 2017;68(7):681–8.  https://doi.org/10.1176/appi.ps.201600130.PubMedCrossRefGoogle Scholar
  38. 38.
    Powers RL, Marks DJ, Miller CJ, Newcorn JH, Halperin JM. Stimulant treatment in children with attention-deficit/hyperactivity disorder moderates adolescent academic outcome. J Child Adolesc Psychopharmacol. 2008;18(5):449–59.  https://doi.org/10.1089/cap.2008.021.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Pan PY, Yeh CB. Impact of depressive/anxiety symptoms on the quality of life of adolescents with ADHD: a community-based 1-year prospective follow-up study. Eur Child Adolesc Psychiatry. 2017;26(6):659–67.  https://doi.org/10.1007/s00787-016-0929-z.PubMedCrossRefGoogle Scholar
  40. 40.
    Baer L, Trivedi MH, Huz I, Rush AJ, Wisniewski SR, Fava M. Prevalence and impact of obsessive-compulsive symptoms in depression: a STAR*D report. J Clin Psychiatry. 2015;76(12):1668–74.  https://doi.org/10.4088/JCP.14m09670.PubMedCrossRefGoogle Scholar
  41. 41.
    Shankman SA, Gorka SM, Katz AC, Klein DN, Markowitz JC, Arnow BA, et al. Side effects to antidepressant treatment in patients with depression and comorbid panic disorder. J Clin Psychiatry. 2017;78(04):433–40.  https://doi.org/10.4088/JCP.15m10370.PubMedCrossRefGoogle Scholar
  42. 42.
    Shaw P, Stringaris A, Nigg J, Leibenluft E. Emotion dysregulation in attention deficit hyperactivity disorder. Am J Psychiatry. 2014;171(3):276–93.  https://doi.org/10.1176/appi.ajp.2013.13070966.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Atomoxetine ADHD and Comorbid MDD Study Group, Bangs ME, Emslie GJ, et al. Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression. J Child Adolesc Psychopharmacol. 2007;17:407–20.CrossRefGoogle Scholar
  44. 44.
    Daviss WB, Bentivoglio P, Racusin R, et al. Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. J Am Acad Child Adolesc Psychiatry. 2001;40(3):307–14.  https://doi.org/10.1097/00004583-200103000-00010.PubMedCrossRefGoogle Scholar
  45. 45.
    Findling RL. Open-label treatment of comorbid depression and attentional disorders with co-administration of serotonin reuptake inhibitors and psychostimulants in children, adolescents, and adults: a case series. J Child Adolesc Psychopharmacol. 1996;6(3):165–75.  https://doi.org/10.1089/cap.1996.6.165.PubMedCrossRefGoogle Scholar
  46. 46.
    Gammon GD, Brown TE. Fluoxetine and methylphenidate in combination for treatment of attention deficit disorder and comorbid depressive disorder. J Child Adolesc Psychopharmacol. 1993;3(1):1–10.  https://doi.org/10.1089/cap.1993.3.1.PubMedCrossRefGoogle Scholar
  47. 47.
    Golubchik P, Kodesh A, Weizman A. Attention-deficit/hyperactivity disorder and comorbid subsyndromal depression: what is the impact of methylphenidate on mood? Clin Neuropharmacol. 2013;36(5):141–5.  https://doi.org/10.1097/WNF.0b013e31829eb204.PubMedCrossRefGoogle Scholar
  48. 48.
    Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, et al. Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005;44(9):915–24.  https://doi.org/10.1097/01.chi.0000169012.81536.38.PubMedCrossRefGoogle Scholar
  49. 49.
    Chang K, Nayar D, Howe M, Rana M. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder. J Child Adolesc Psychopharmacol. 2009;19(5):547–51.  https://doi.org/10.1089/cap.2009.0030.PubMedCrossRefGoogle Scholar
  50. 50.
    Findling RL, Short EJ, McNamara NK, et al. Methylphenidate in the treatment of children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(11):1445–53.  https://doi.org/10.1097/chi.0b013e31814b8d3b.PubMedCrossRefGoogle Scholar
  51. 51.
    Hah M, Chang K. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders. J Child Adolesc Psychopharmacol. 2005;15(6):996–1004.  https://doi.org/10.1089/cap.2005.15.996.PubMedCrossRefGoogle Scholar
  52. 52.
    Scheffer RE, Kowatch RA, Carmody T, Rush AJ. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry. 2005;162(1):58–64.  https://doi.org/10.1176/appi.ajp.162.1.58.PubMedCrossRefGoogle Scholar
  53. 53.
    Blader JC, Schooler NR, Jensen PS, et al. Adjunctive divalproex versus placebo for children with ADHD and aggression refractory to stimulant monotherapy. Am J Psychiatry. 2009;166(12):1392–401.  https://doi.org/10.1176/appi.ajp.2009.09020233.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Baweja R, Belin PJ, Humphrey HH, Babocsai L, Pariseau ME, Waschbusch DA, et al. The effectiveness and tolerability of central nervous system stimulants in school-age children with attention-deficit/hyperactivity disorder and disruptive mood dysregulation disorder across home and school. J Child Adolesc Psychopharmacol. 2016;26(2):154–63.  https://doi.org/10.1089/cap.2015.0053.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Dickstein DP, Towbin KE, Van Der Veen JW, Rich BA, Brotman MA, Knopf L, et al. Randomized double-blind placebo-controlled trial of lithium in youths with severe mood dysregulation. J Child Adolesc Psychopharmacol. 2009;19(1):61–73.  https://doi.org/10.1089/cap.2008.044.PubMedPubMedCentralCrossRefGoogle Scholar
  56. 56.
    • Fernandez de la Cruz L, Simonoff E, McGough JJ, et al. Treatment of children with attention-deficit/hyperactivity disorder (ADHD) and irritability: results from the multimodal treatment study of children with ADHD (MTA). J Am Acad Child Adolesc Psychiatry. 2015;54(1):62–70 e3. This study used data from the Multimodal Treatment Study of Children with ADHD (MTA) to examine whether ADHD treatment is effective in treating irritability and to examine how irritability influences ADHD treatment outcomes.  https://doi.org/10.1016/j.jaac.2014.10.006.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BSG, McNamara NK, et al. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014;53(1):47–60 e1.  https://doi.org/10.1016/j.jaac.2013.09.022.PubMedCrossRefGoogle Scholar
  58. 58.
    Gadow KD, Arnold LE, Molina BS, et al. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014;53(9):948–59 e1.  https://doi.org/10.1016/j.jaac.2014.05.008.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    • Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, et al. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015;25(3):213–224. This study examines the parent and child characteristics as predictors and moderators of response in the four-site Treatment of Severe Childhood Aggression (TOSCA) study.  https://doi.org/10.1089/cap.2014.0109.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Waxmonsky J, Pelham WE, Gnagy E, Cummings MR, O'Connor B, Majumdar A, et al. The efficacy and tolerability of methylphenidate and behavior modification in children with attention-deficit/hyperactivity disorder and severe mood dysregulation. J Child Adolesc Psychopharmacol. 2008;18(6):573–88.  https://doi.org/10.1089/cap.2008.065.PubMedPubMedCentralCrossRefGoogle Scholar
  61. 61.
    Waxmonsky JG, Waschbusch DA, Belin P, Li T, Babocsai L, Humphery H, et al. A randomized clinical trial of an integrative group therapy for children with severe mood dysregulation. J Am Acad Child Adolesc Psychiatry. 2016;55(3):196–207.  https://doi.org/10.1016/j.jaac.2015.12.011.PubMedCrossRefGoogle Scholar
  62. 62.
    Abikoff H, McGough J, Vitiello B, McCracken J, Davies M, Walkup J, et al. Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(5):418–27.  https://doi.org/10.1097/01.chi.0000155320.52322.37.PubMedCrossRefGoogle Scholar
  63. 63.
    Diamond IR, Tannock R, Schachar RJ. Response to methylphenidate in children with ADHD and comorbid anxiety. J Am Acad Child Adolesc Psychiatry. 1999;38(4):402–9.  https://doi.org/10.1097/00004583-199904000-00012.PubMedCrossRefGoogle Scholar
  64. 64.
    DuPaul GJ, Barkley RA, McMurray MB. Response of children with ADHD to methylphenidate: interaction with internalizing symptoms. J Am Acad Child Adolesc Psychiatry. 1994;33(6):894–903.  https://doi.org/10.1097/00004583-199407000-00016.PubMedCrossRefGoogle Scholar
  65. 65.
    Gadow KD, Nolan EE, Sverd J, Sprafkin J, Schwartz J. Anxiety and depression symptoms and response to methylphenidate in children with attention-deficit hyperactivity disorder and tic disorder. J Clin Psychopharmacol. 2002;22(3):267–74.  https://doi.org/10.1097/00004714-200206000-00007.PubMedCrossRefGoogle Scholar
  66. 66.
    Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1119–27.  https://doi.org/10.1097/chi.0b013e3180ca8385.PubMedCrossRefGoogle Scholar
  67. 67.
    Golubchik P, Sever J, Weizman A. Methylphenidate treatment in children with attention deficit hyperactivity disorder and comorbid social phobia. Int Clin Psychopharmacol. 2014;29(4):212–5.  https://doi.org/10.1097/YIC.0000000000000029.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Pliszka SR. Effect of anxiety on cognition, behavior, and stimulant response in ADHD. J Am Acad Child Adolesc Psychiatry. 1989;28(6):882–7.  https://doi.org/10.1097/00004583-198911000-00012.PubMedCrossRefGoogle Scholar
  69. 69.
    Taylor E, Schachar R, Thorley G, Wieselberg HM, Everitt B, Rutter M. Which boys respond to stimulant medication? A controlled trial of methylphenidate in boys with disruptive behaviour. Psychol Med. 1987;17(01):121–43.  https://doi.org/10.1017/S0033291700013039.PubMedCrossRefGoogle Scholar
  70. 70.
    Ter-Stepanian M, Grizenko N, Zappitelli M, Joober R. Clinical response to methylphenidate in children diagnosed with attention-deficit hyperactivity disorder and comorbid psychiatric disorders. Can J Psychiatr. 2010;55(5):305–12.  https://doi.org/10.1177/070674371005500506.CrossRefGoogle Scholar
  71. 71.
    Costin J, Vance A, Barnett R, O'Shea M, Luk ESL. Attention deficit hyperactivity disorder and comorbid anxiety: practitioner problems in treatment planning. Child Adolesc Mental Health. 2002;7(1):16–24.  https://doi.org/10.1111/1475-3588.00005.CrossRefGoogle Scholar
  72. 72.
    • Halldorsdottir T, Ollendick TH, Ginsburg G, Sherrill J, Kendall PC, Walkup J, et al. Treatment outcomes in anxious youth with and without comorbid ADHD in the CAMS. J Clin Child Adolesc Psychol. 2015;44(6):985–991. This study examines the influence of ADHD on acute treatment response, remission rates, and maintenance of gains at 6-month follow-up in children with anxiety who received CBT alone, pharmacotherapy alone, the combination of CBT, and pharmacotherapy or placebo in the Child Adolescent Multimodal Study (CAMS).  https://doi.org/10.1080/15374416.2014.952008.PubMedCrossRefGoogle Scholar
  73. 73.
    Jarrett MA, Ollendick TH. Treatment of comorbid attention-deficit/hyperactivity disorder and anxiety in children: a multiple baseline design analysis. J Consult Clin Psychol. 2012;80(2):239–44.  https://doi.org/10.1037/a0027123.PubMedCrossRefGoogle Scholar
  74. 74.
    • Maric M, van Steensel FJ, Bogels SM. Parental involvement in CBT for anxiety-disordered youth revisited: family CBT outperforms child CBT in the long term for children with comorbid ADHD symptoms. J Atten Disord. 2015:108705471557399.  https://doi.org/10.1177/1087054715573991. This study describes the efficacy of child cognitive-behavioral therapy (CCBT) versus family CBT (FCBT) in anxiety-disordered youth with high and low comorbid ADHD symptoms.
  75. 75.
    Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK. Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine. J Child Adolesc Psychopharmacol. 2014;24(8):426–34.  https://doi.org/10.1089/cap.2014.0005.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Chang Z, D’Onofrio BM, Quinn PD, et al. Medication for attention-deficit/hyperactivity disorder and risk for depression: a nationwide longitudinal cohort study. Biol Psychiatry. 2016;80(12):916–22.  https://doi.org/10.1016/j.biopsych.2016.02.018.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Biederman J, Monuteaux MC, Spencer T, Wilens TE, Faraone SV. Do stimulants protect against psychiatric disorders in youth with ADHD? A 10-year follow-up study. Pediatrics. 2009;124(1):71–8.  https://doi.org/10.1542/peds.2008-3347.PubMedPubMedCentralCrossRefGoogle Scholar
  78. 78.
    Keller MB, Ryan ND, Strober M, et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001;40(7):762–72.  https://doi.org/10.1097/00004583-200107000-00010.PubMedCrossRefGoogle Scholar
  79. 79.
    Nevels RM, Gontkovsky ST, Williams BE. Paroxetine—the antidepressant from hell? Probably not, but caution required. Psychopharmacol Bull. 2016;46(1):77–104.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Kratochvil CJ, May DE, Silva SG, Madaan V, Puumala SE, Curry JF, et al. Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study. J Child Adolesc Psychopharmacol. 2009;19(5):519–27.  https://doi.org/10.1089/cap.2008.0143.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Burke JD. An affective dimension within oppositional defiant disorder symptoms among boys: personality and psychopathology outcomes into early adulthood. J Child Psychol Psychiatry. 2012;53(11):1176–83.  https://doi.org/10.1111/j.1469-7610.2012.02598.x.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Brotman MA, Kircanski K, Stringaris A, Pine DS, Leibenluft E. Irritability in youths: a translational model. Am J Psychiatry. 2017;174(6):520–32.  https://doi.org/10.1176/appi.ajp.2016.16070839.PubMedCrossRefGoogle Scholar
  83. 83.
    Bridge JA, Iyengar S, Salary CB, Barbe RP, Birmaher B, Pincus HA, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA. 2007;297(15):1683–96.  https://doi.org/10.1001/jama.297.15.1683.PubMedCrossRefGoogle Scholar
  84. 84.
    Lavretsky H, Reinlieb M, St Cyr N, et al. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172(6):561–9.  https://doi.org/10.1176/appi.ajp.2014.14070889.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, et al. The efficacy of psychostimulants in major depressive episodes: a systematic review and meta-analysis. J Clin Psychopharmacol. 2017;37(4):412–8.  https://doi.org/10.1097/JCP.0000000000000723.PubMedCrossRefGoogle Scholar
  86. 86.
    Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1996;35(10):1314–21.  https://doi.org/10.1097/00004583-199610000-00018.PubMedCrossRefGoogle Scholar
  87. 87.
    Waxmonsky JG. Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults. Essent Psychopharmacol. 2005;6(5):262–76.PubMedGoogle Scholar
  88. 88.
    Mongia M, Hechtman L. Cognitive behavior therapy for adults with attention-deficit/hyperactivity disorder: a review of recent randomized controlled trials. Curr Psychiatry Rep. 2012;14(5):561–7.  https://doi.org/10.1007/s11920-012-0303-x.PubMedCrossRefGoogle Scholar
  89. 89.
    Pliszka SR, Greenhill LL, Crismon ML, et al. The Texas Children’s Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Attention-Deficit/Hyperactivity Disorder. Part I. Attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(7):908–19.  https://doi.org/10.1097/00004583-200007000-00021.PubMedCrossRefGoogle Scholar
  90. 90.
    Consoli A, Bouzamondo A, Guile JM. Comorbidity with ADHD decreases response to pharmacotherapy in children and adolescents with acute mania: evidence from a metaanalysis. Can J Psychiatr. 2007;52(5):323–8.  https://doi.org/10.1177/070674370705200507.CrossRefGoogle Scholar
  91. 91.
    Fristad MA. Psychoeducational treatment for school-aged children with bipolar disorder. Dev Psychopathol. 2006;18(4):1289–306.  https://doi.org/10.1017/S0954579406060627.PubMedCrossRefGoogle Scholar
  92. 92.
    West AE, Henry DB, Pavuluri MN. Maintenance model of integrated psychosocial treatment in pediatric bipolar disorder: a pilot feasibility study. J Am Acad Child Adolesc Psychiatry. 2007;46(2):205–12.  https://doi.org/10.1097/01.chi.0000246068.85577.d7.PubMedCrossRefGoogle Scholar
  93. 93.
    Stringaris A. National Institute of Mental Health (NIMH). A controlled trial of serotonin reuptake inhibitors added to stimulant medication in youth with severe mood dysregulation. ClinicalTrials.gov [Internet]. [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 Available from: https://clinicaltrials.gov/ct/show/NCT00794040. Accessed Oct 29 2017.
  94. 94.
    Coughlin CG, Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Bloch MH. Meta-analysis: reduced risk of anxiety with psychostimulant treatment in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015;25(8):611–7.  https://doi.org/10.1089/cap.2015.0075.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Schwartz S, Correll CU. Efficacy and safety of atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder: results from a comprehensive meta-analysis and metaregression. J Am Acad Child Adolesc Psychiatry. 2014;53(2):174–87.  https://doi.org/10.1016/j.jaac.2013.11.005.PubMedCrossRefGoogle Scholar
  96. 96.
    Walkup JT, Albano AM, Piacentini J, Birmaher B, Compton SN, Sherrill JT, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008;359(26):2753–66.  https://doi.org/10.1056/NEJMoa0804633.PubMedPubMedCentralCrossRefGoogle Scholar
  97. 97.
    Pelham WE Jr, Fabiano GA, Massetti GM. Evidence-based assessment of attention deficit hyperactivity disorder in children and adolescents. J Clin Child Adolesc Psychol. 2005;34(3):449–76.  https://doi.org/10.1207/s15374424jccp3403_5.PubMedCrossRefGoogle Scholar
  98. 98.
    Markowitz JS, Patrick KS. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet. 2001;40(10):753–72.  https://doi.org/10.2165/00003088-200140100-00004.PubMedCrossRefGoogle Scholar
  99. 99.
    Markowitz JS, Patrick KS. The clinical pharmacokinetics of amphetamines utilized in the treatment of attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2017;27(8):678–89.  https://doi.org/10.1089/cap.2017.0071.PubMedCrossRefGoogle Scholar
  100. 100.
    Kohn MR, Tsang TW, Clarke SD. Efficacy and safety of atomoxetine in the treatment of children and adolescents with attention deficit hyperactivity disorder. Clin Med Insights Pediatr. 2012;6:95–162.  https://doi.org/10.4137/CMPed.S7868.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    NextWave Pharmaceuticals. Product information: QUILLIVANT (TM) XR oral extended release suspension mHoersC, CA, 2012.Google Scholar
  102. 102.
    United States Product Information. ADDERALL XR(R) oral capsules dsdsaamasocW, PA, 2013.Google Scholar
  103. 103.
    Feldman HM, Reiff MI. Clinical practice. Attention deficit-hyperactivity disorder in children and adolescents. N Engl J Med. 2014;370(9):838–46.  https://doi.org/10.1056/NEJMcp1307215.PubMedCrossRefGoogle Scholar
  104. 104.
    Pelham W. Pharmacotherapy for children with ADHD. School Psychol Rev. 1993:199–227.Google Scholar
  105. 105.
    Barkley RA, McMurray MB, Edelbrock CS, Robbins K. Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics. 1990;86(2):184–92.PubMedGoogle Scholar
  106. 106.
    Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry. 2015;54(9):728–36.  https://doi.org/10.1016/j.jaac.2015.06.011.PubMedCrossRefGoogle Scholar
  107. 107.
    Childress AC, Arnold V, Adeyi B, Dirks B, Babcock T, Scheckner B, et al. The effects of lisdexamfetamine dimesylate on emotional lability in children 6 to 12 years of age with ADHD in a double-blind placebo-controlled trial. J Atten Disord. 2014;18(2):123–32.  https://doi.org/10.1177/1087054712448252.PubMedCrossRefGoogle Scholar
  108. 108.
    Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry. 2006;45(11):1284–93.  https://doi.org/10.1097/01.chi.0000235077.32661.61.PubMedCrossRefGoogle Scholar
  109. 109.
    Research Units on Pediatric Psychopharmacology Autism. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62:1266–74.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of PsychiatryPenn State College of MedicineHersheyUSA
  2. 2.Penn State College Of MedicineHersheyUSA

Personalised recommendations